Epigenetic therapy for colorectal cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic alterations, including DNA methylation, histone acetylation, and microRNA expression changes, are implicated in colorectal cancer (CRC) progression.
• These epigenetic modifications influence all stages of tumor development, from initial growth to metastasis.

Purpose of the Study:

• To review the current status and implications of epigenetic therapy in colorectal cancer (CRC).
• To highlight the potential of targeting reversible epigenetic changes for CRC treatment and personalized medicine.

Main Methods:

• Literature review on epigenetic alterations in CRC.
• Analysis of studies investigating epigenetic therapies, specifically DNA demethylating and histone acetylating agents.

Main Results:

• Aberrations in DNA methylation, histone acetylation, and miRNA expression are key drivers of CRC.
• DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) demonstrate promising efficacy in managing CRC progression.

Conclusions:

• Epigenetic alterations are crucial in CRC pathogenesis and progression.
• Epigenetic therapies, including DNMTi and HDACi, represent a viable strategy for CRC treatment.
• The reversibility of epigenetic changes supports the development of personalized medicine approaches for CRC.